VYNE VYNE Therapeutics Inc

Price (delayed)

$2.1

Market cap

$30.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.21

Enterprise value

$11.57M

VYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

Highlights
VYNE's EPS has soared by 88% YoY and by 56% QoQ
VYNE's debt is down by 16% since the previous quarter
The net income has increased by 13% YoY but it has decreased by 2.2% from the previous quarter
VYNE's equity is down by 6% since the previous quarter

Key stats

What are the main financial stats of VYNE
Market
Shares outstanding
14.53M
Market cap
$30.51M
Enterprise value
$11.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.36
Price to sales (P/S)
211.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.35
Earnings
Revenue
$423,000
EBIT
-$29.08M
EBITDA
-$29.08M
Free cash flow
-$27.85M
Per share
EPS
-$1.21
Free cash flow per share
-$0.65
Book value per share
$5.91
Revenue per share
$0.01
TBVPS
$2.15
Balance sheet
Total assets
$91.68M
Total liabilities
$8.31M
Debt
$180,000
Equity
$83.37M
Working capital
$83.29M
Liquidity
Debt to equity
0
Current ratio
13.02
Quick ratio
12.41
Net debt/EBITDA
0.65
Margins
EBITDA margin
-6,874.5%
Gross margin
100%
Net margin
-6,874.5%
Operating margin
-7,272.8%
Efficiency
Return on assets
-49.8%
Return on equity
-57.9%
Return on invested capital
-96.4%
Return on capital employed
-34.3%
Return on sales
-6,874.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VYNE stock price

How has the VYNE Therapeutics stock price performed over time
Intraday
-1.41%
1 week
-6.67%
1 month
15.38%
1 year
-48.02%
YTD
-9.87%
QTD
6.6%

Financial performance

How have VYNE Therapeutics's revenue and profit performed over time
Revenue
$423,000
Gross profit
$423,000
Operating income
-$30.76M
Net income
-$29.08M
Gross margin
100%
Net margin
-6,874.5%
VYNE's net margin is up by 18% year-on-year but it is down by 2.4% since the previous quarter
The net income has increased by 13% YoY but it has decreased by 2.2% from the previous quarter
VYNE's operating margin is up by 8% year-on-year but it is down by 5% since the previous quarter
VYNE's gross profit is up by 6% YoY

Growth

What is VYNE Therapeutics's growth rate over time

Valuation

What is VYNE Therapeutics stock price valuation
P/E
N/A
P/B
0.36
P/S
211.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.35
VYNE's EPS has soared by 88% YoY and by 56% QoQ
VYNE's P/B is 82% below its 5-year quarterly average of 2.0 and 49% below its last 4 quarters average of 0.7
VYNE's equity is down by 6% since the previous quarter
VYNE's P/S is 94% above its last 4 quarters average of 109.0
The revenue is up by 6% year-on-year

Efficiency

How efficient is VYNE Therapeutics business performance
VYNE's return on invested capital has surged by 94% year-on-year and by 56% since the previous quarter
The ROE rose by 37% YoY and by 27% QoQ
The ROA has grown by 34% YoY and by 22% from the previous quarter
VYNE's ROS is up by 18% YoY but it is down by 2.4% QoQ

Dividends

What is VYNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VYNE.

Financial health

How did VYNE Therapeutics financials performed over time
The current ratio has surged by 197% year-on-year and by 2.3% since the previous quarter
VYNE Therapeutics's total assets has soared by 160% YoY but it has decreased by 6% from the previous quarter
VYNE's debt is 100% smaller than its equity
VYNE's debt is down by 16% since the previous quarter
VYNE's equity is down by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.